AMORFIX LIFE SCIENCES TO PRESENT AT BIOPARTNERING NORTH AMERICA

(TSX: AMF)

TORONTO, Feb. 24 /CNW/ - Amorfix Life Sciences (TSX: AMF), a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced that the company has been selected by the International Trade Branch and the Ontario Ministry of Economic Development and Trade in partnership with the Ontario BioScience Industry Organization to present a corporate overview at the Biopartnering North America meeting in Vancouver, Canada from February 27 through March 1, 2011. 

Amorfix is one of seven healthcare companies selected as part of the Ontario delegation to participate in this premier international partnering event. Dr. Robert Gundel, Amorfix President and CEO, will present a corporate overview highlighting Amorfix's proprietary ProMIS discovery technology, the Epitope Protection technology and their product pipeline of innovative antibody therapeutics and diagnostics. This will be followed by one-on-one meetings with pharmaceutical companies to discuss potential product collaborations and partnership deals.

"We are very pleased to be participating in one of the premier international partnering events and to have the opportunity to present our technology and product pipeline to this audience," said Dr. Robert Gundel, President and CEO. "We have made significant progress on the development of our cancer therapeutic antibody programs and our human Alzheimer's disease diagnostic and are actively seeking partners for a variety of business arrangements." Amorfix will be presenting the corporate overview on Monday, February 28, 2011 at 2:00 pm Pacific time.  

About Amorfix
Amorfix Life Sciences Ltd. (TSX:AMF) is a product development company developing therapeutic products and diagnostic devices targeting misfolded protein diseases including Alzheimer's Disease (AD), cancers, and ALS. Amorfix utilizes its computational discovery platform, ProMIS™, to predict novel Disease Specific Epitopes ("DSEs") on the molecular surface of misfolded proteins. Amorfix's lead programs include therapeutics and companion diagnostics for cancers, antibodies and vaccines to DSEs in ALS and AD diagnostic tests. In addition, Amorfix's proprietary Epitope Protection™ technology enables it to specifically identify very low levels of misfolded proteins in a biological sample. The Company's diagnostic programs include an ultrasensitive method for the detection of aggregated beta-Amyloid in brain tissue, CSF and blood from animal models of AD, months prior to observable amyloid formation, and development of a human screening test for AD. For more information about Amorfix, visit www.amorfix.com.

Forward-Looking Statements
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Amorfix Life Sciences Ltd.

For further information:

Dr. Robert Gundel
President and Chief Executive Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6957
Fax: (416) 847-6899
bob.gundel@amorfix.com
        Janet Clennett
Acting Chief Financial Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6926
Fax: (416) 847-6899
janet.clennett@amorfix.com

Profil de l'entreprise

Amorfix Life Sciences Ltd.

Renseignements sur cet organisme


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.